AQX-1125 is the company's most advanced product and was selected as the lead product because it is a potent activator of SHIP1. AQX-1125 is being developed for the treatment of blood and immune disorders and has many desirable drug attributes that make it especially compelling:

• it is highly selective for SHIP1


• it is a small molecule (<500 daltons)


• it has a scalable synthesis


• it has shown potent anti-inflammatory activity both in vitro and in vivo


• it can be dosed once-a-day orally


• it has excellent pharmaceutical properties